2-methyl-4-chloro-N-methylanilin | 30273-07-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-methyl-4-chloro-N-methylanilin
• 英文别名: N-methyl-2-methyl-4-chloroaniline；4-chloro-N,2-dimethylbenzenamine；4-chloro-N,2-dimethyl-aniline；N-methyl-4-chloro-2-methylaniline；4-Chloro-2,N-dimethylaniline；4-chloro-N,2-dimethylaniline
• CAS: 30273-07-5
• 化学式: C₈H₁₀ClN
• mdl: MFCD10000395
• 分子量: 155.627
• InChiKey: OWSBCCVKVBSMGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-methyl-4-chloro-N-methylanilin 在 盐酸 、 正丁基锂 作用下， 生成 5-chloro-1-methylindolin-2-one
  参考文献：
  名称：

  Rewcastle, Gordon W.; Denny, William A., Heterocycles, 1994, vol. 37, # 2, p. 701 - 708

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氯-2-甲基苯胺 、 碘甲烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 以36%的产率得到2-methyl-4-chloro-N-methylanilin
  参考文献：
  名称：

  芳烃和苄型的C铱催化区域选择性硅烷化？仲胺指导的H键

  摘要：

  本文报道的是铱催化的苄胺芳族CH键和2 N-二烷基苯胺的苄基CH键的区域选择性甲硅烷基化反应。在该方法中，通过苄胺或苯胺与二乙基硅烷的脱氢偶联原位生成的（氢化）甲硅烷基胺在氨基的CH键γ处进行选择性甲硅烷基化。这种甲硅烷基化的产物适用于随后的氧化，卤化和交叉偶联反应，以递送苄胺和芳胺衍生物。

  DOI：

  10.1002/anie.201404620

文献信息

• Catalytic methylation of aromatic amines with formic acid as the unique carbon and hydrogen source
  作者：Solène Savourey、Guillaume Lefèvre、Jean-Claude Berthet、Thibault Cantat

  DOI：10.1039/c4cc05908e

  日期：——

  A novel methodology is presented for the direct methylation of amines, using formic acid as a unique source of carbon and hydrogen. Based on ruthenium(II) catalysts, the formation of the N-CH3 group proceeds via an efficient formylation/transfer hydrogenation pathway.

  使用甲酸作为碳和氢的独特来源，提出了一种用于胺直接甲基化的新方法。基于钌（II）催化剂，N-CH3基团的形成通过有效的甲酰化/转移氢化途径进行。
• INHIBITORS OF TISSUE TRANSGLUTAMINASE 2 (TG2) AND USES THEREOF
  申请人：Northwestern University

  公开号：US20210276960A1

  公开（公告）日：2021-09-09

  Disclosed are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and pharmaceutical compositions for treating a subject in need thereof. The disclosed compounds inhibit the activity of tissue transglutaminase 2 (TG2). As such, the disclosed compounds and pharmaceutical compositions may be utilized in methods for treating a subject having or at risk for developing a disease or disorder that is associated with TG2 activity which may be cell proliferative diseases and disorders such as cancer.

  揭示了化合物、包含这些化合物的药物组合物，以及利用这些化合物和药物组合物治疗需要的受试者的方法。所述的化合物抑制组织转谷氨酰胺酶2（TG2）的活性。因此，这些揭示的化合物和药物组合物可以用于治疗患有或有发展与TG2活性相关的疾病或紊乱的受试者的方法，这些疾病或紊乱可能是与细胞增殖相关的疾病或紊乱，如癌症。
• [EN] NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF<br/>[FR] NOUVEAU COMPOSÉ, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  申请人：DAEGU GYEONGBUK MEDICAL INNOVATION FOUND

  公开号：WO2021145729A1

  公开（公告）日：2021-07-22

  The present invention relates to a method for preparing a biomaterial having selectively functionalized tyrosine, a biomaterial having selectively functionalized tyrosine, and a pharmaceutical composition containing the same as an active ingredient. The method for preparing a biomaterial to which a compound represented by formula 2 is coupled, of the present invention, allows the compound represented by formula 2 to be selectively coupled, in a high yield in a biomaterial, to tyrosine, which is present on the surface of an aqueous solution such that the coupling thereof to amino acids other than tyrosine does not occur and, when only one tyrosine is present, heterogeneous mixtures are not present and the inherent activity of the biomaterial is maintained, and thus the compound can be effectively used as a pharmaceutical composition containing a biomaterial drug as an active ingredient. In addition, the method can selectively functionalize tyrosine, and thus can be effectively used for tyrosine functionalization in a biomaterial.

  本发明涉及一种制备具有选择性功能化酪氨酸的生物材料的方法，具有选择性功能化酪氨酸的生物材料，以及含有该生物材料作为活性成分的药物组合物。本发明的一种制备生物材料的方法，其中将由式2表示的化合物偶联到生物材料，使得该化合物能够选择性地偶联到酪氨酸，且在生物材料中的产率较高，酪氨酸位于水溶液表面，使得其与酪氨酸以外的氨基酸不发生偶联，当只有一个酪氨酸存在时，不会出现异质混合物，同时保持生物材料的固有活性，因此该化合物可以有效地用作含有生物材料药物的药物组合物的活性成分。此外，该方法可以选择性功能化酪氨酸，因此可以有效地用于生物材料中的酪氨酸功能化。
• PREPARATION AND UTILITY OF SUBSTITUTED CARBOXYLIC ACID COMPOUNDS
  申请人：Gant Thomas G.

  公开号：US20070276042A1

  公开（公告）日：2007-11-29

  The present disclosure is directed to modulators of cyclooxygenase (COX) enzymes and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of the severity and duration of non-specific pain, tension-type pain, headache, migraine, lower back pain, sciatica, dental pain, muscular pain, pain associated with acute soft tissue injuries, bursitis, tendonitis, lumbago, periarthritis, tennis elbow, sprains, strains, muscular problems associated with sports injuries, muscular problems associated with accidents, period pain, primary dysmenorrhoea, acute sore throat pain, osteoarthritis, rheumatoid arthritis, cancer, any disorder requiring analgesic response, any disorder requiring anti-inflammatory response, any disorder requiring antipyretic response, any conditions mediated by cyclooxygenase, cystic fibrosis, dementia, Alzheimer's disease, and/or conditions mediated by levels of β-amyloid are described.

  本公开涉及环氧合酶（COX）酶的调节剂及其药用盐和前药，其化学合成，以及这些化合物的医学用途，用于治疗和/或管理非特异性疼痛、紧张性疼痛、头痛、偏头痛、腰痛、坐骨神经痛、牙痛、肌肉疼痛、急性软组织损伤引起的疼痛、滑囊炎、肌腱炎、腰痛、周围关节炎、网球肘、扭伤、拉伤、与运动损伤相关的肌肉问题、与事故相关的肌肉问题、经期疼痛、原发性痛经、急性喉咙疼痛、骨关节炎、类风湿性关节炎、癌症、需要镇痛反应的任何疾病、需要抗炎反应的任何疾病、需要退热反应的任何疾病、任何通过环氧合酶介导的病症、囊性纤维化、痴呆、阿尔茨海默病和/或通过β-淀粉样蛋白水平介导的病症。
• [EN] 3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES<br/>[FR] DÉRIVÉS DE 3,7-DIAZABICYCLO[3.3.1]NONANE ET DE 9-OXA-3,7- DIAZABICYCLO[3.3.1]NONANE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2013050938A1

  公开（公告）日：2013-04-11

  The present invention relates to 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7- diazabicyclo[3.3.1 ]nonane derivatives of formula (I) wherein Ar1 and Ar2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及式（I）的3,7-二氮杂双环[3.3.1]壬烷和9-氧-3,7-二氮杂双环[3.3.1]壬烷衍生物，其中Ar1和Ar2如描述中所述，其制备方法，其药学上可接受的盐，以及作为药物的用途，含有一种或多种式（I）化合物的药物组合物，特别是其用作促进睡眠受体拮抗剂。